Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,443.00
+272.00 (23.23%)
Last updated: Aug 14, 2025
-14.11%
Market Cap 75.11B
Revenue (ttm) 12.77B
Net Income (ttm) -8.28B
Shares Out 56.05M
EPS (ttm) -152.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,692,131
Average Volume 1,539,079
Open 1,196.00
Previous Close 1,171.00
Day's Range 1,196.00 - 1,499.00
52-Week Range 1,157.00 - 2,935.00
Beta 0.65
RSI 45.81
Earnings Date Mar 14, 2025

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 97
Stock Exchange KOSDAQ
Ticker Symbol 217730
Full Company Profile

Financial Performance

In 2023, Kangstem Biotech's revenue was 12.70 billion, a decrease of -22.06% compared to the previous year's 16.30 billion. Losses were -21.95 billion, 8.47% more than in 2022.

Financial Statements

News

There is no news available yet.